.After antibody-drug conjugate (ADC) expert Seagen was offered to Pfizer in 2015 for an immense $43 ...
.On the heels of a phase 3 win that failed to blow away investors, Ironwood Pharmaceuticals is back ...
.Don't quit Monte Rosa Therapies now. The Boston-based biotech is actually enjoying after authorizin...
.Accept to today's Chutes & Ladders, our roundup of considerable management hirings, shootings an...
.Commemorating his provider's upsized going public (IPO), Septerna CEO Jeffrey Finer rang the openin...
.AbbVie has actually gone back to the source of its antipsychotic goliath Vraylar trying to find an ...
.GenSight Biologics is weeks away from lacking amount of money. Once again. The biotech merely posse...
.Monopar Therapies is recuperating a medication coming from the dump of AstraZeneca's unusual ailmen...
.With new records out on Arcus Biosciences' speculative HIF-2a prevention, one group of professional...
.After forming a genetics treatment partnership with Dyno Therapies in 2020, Roche is actually back ...